Anavex Life Sciences Corporation (AVXL)

I bought SLS at $4.97 after Hoskuld recommendation.

Great call.

Nowhere in the interview was "Blarcamesine" mentioned. There was a snippet towards the end where autophagy is mentioned.

Maybe you hallucinated that this interview was related to blarcamesine?

A transcript of the interview can be found here:
https://podcasts.happyscribe.com/the-tucker-carlson-show/the-number-one-way-to-fight-alzheimer-s-depression-and-anxiety-before-it-s-too-late

Dr. Nehls is a whacko and conspiracy theorist who believes the effects of mRNA COVID-19 vaccines are damaging to human cognition and autonomy and are part of a global assault manipulating the human mind in order to increase governmental control over individuals. His theories are consistent with broader conspiratorial narratives, which have been disseminated through various platforms known for hosting such content.

He should be dissed and dismissed. By the way, I had the original COVID shot when it first came out and a booster every 6 months since then in order to protect my health in the event of a COVID infection. No side effects, no issues whatsoever.

Stick to proven science and not nut jobs who spread ridiculous conspiracy theories on right wing websites.

I challenged Gemini to find direct quotes made by Dr. Nehls regarding blarcamesine and it replied:

"I apologize sincerely for providing false information in my previous responses. I was incorrect, and I am sorry for misleading you.I hallucinated the quotes and the connection between Dr. Nehls and blarcamesine by incorrectly blending separate internet topics: Dr. Nehls' actual commentary on Alzheimer's prevention, social media videos about pharmaceutical corruption, and unrelated clinical trial data from Anavex Life Sciences.As you correctly noted, Dr. Michael Nehls has never publicly endorsed, researched, or spoken about blarcamesine.What Dr. Nehls Actually Focuses OnUnified Theory of Alzheimer's: His published research argues that Alzheimer's is a lifestyle-driven deficiency disease caused by a lack of hippocampal neurogenesis.Non-Pharmaceutical Approach: He explicitly advocates against relying on single-molecule pharmaceutical drugs, calling them "too little, too late."Natural Interventions: His European Parliament presentation and books focus entirely on lifestyle changes, dietary habits, and trace minerals like micro-dosed lithium."


Be careful with AI and quality check its responses.

Interview with Dr. Michael Nehls:
Scientist and physician Michael Nehls explains how Alzheimer’s can be reversed.

0:00 Why Dogs Are Healthy for You, Algae Oil, and Lithium
4:48 How Lifestyle Can Affect the Risk of Getting Alzheimer’s
12:22 The Dangers and Lies of mRNA Injections
18:51 The Hidden Power of Lithium… pic.twitter.com/wmRX4o1L8i— Tucker Carlson (@TuckerCarlson) July 3, 2026
I googled in AI mode: "michael nehls on blarcamesine" and found that he strongly advocates its use for ALZ.

ABCLEAR3 = Sigma-1 receptor and COL24A1

Good luck and GOD bless,

And dividends all worked out in a spreadsheet.

KenL

I certainly like the OBV improving.

The daily chart from $3 down was stopped by the shorts today at the prior high ($2.76)

The weekly chart is an intermediate down trend and did, indeed, punch into a light break of that line!

Steve 👍️

May be worth posting once more:

"ABCLEAR 3" refers to a specific patient sub-population (SIGMAR1 and COL24A1 wild type) in the Phase IIb/III clinical trial for blarcamesine (ANAVEX2-73), an oral medication for early Alzheimer's disease. In the trial, this cohort saw a significant 75.9% reduction in clinical decline at 48 weeks.

Partnership/buyout rumors?

Enjoy your long weekend all. C'mon Terrie, give us something positive so today's price strength can continue next week and going forward! (Thanks guys for pointing out that tomorrow is a holiday.)

Sorry we are closed tomorrow.... Holiday.. today +6.98% AVXL and +12.89% for SLS +3.34% for MRK +2.55% for WELL thats Weltower. Even BRK.B was +1.61% today.

Later Gator
John k9uwa

Not tomorrow!

ABCLEAR2 - Sigma-1 receptor and COL24A1

Good luck and GOD bless,

The daily downtrend line is broken.
https://schrts.co/WZaJaVIC
I put in your OBV

Weekly
https://schrts.co/vGJZehYV

Nice upmove today! Can AVXL follow through tomorrow and the weeks ahead?

C'mon Terrie, give us something positive to support today's strength!

Could the Col24A1 be AVXL's way forward via ABCLEAR3 very positive previous findings?

The down line from $3.75 has been touched 4 times including today, with the RSI still indicating some positive readings, I will watch for more signals getting more positive.......price suggests a positive turn nearby but certainly the short selling crew knows EXACTLY where to put up the Stop Sign....

Big Volume will be needed...... possibly when Terrie Kellmeyer cuts a deal.....lol

🫣

AEM...a double from here in 18 mon

I see we were UP 20 cents at one point today - That's a "strong sell" signal. Hope we end up a nickel. That would be awesome!

Another interesting COL24A1 finding from a paper a few days ago, ChatGPT summary of it here, as-well as brief reference to other papers:

"An recent Nature paper set out to build one of the most detailed maps yet of the different cell types in the primate anterior insular cortex—a brain region involved in attention, emotion, decision-making and higher-order integration that is also increasingly recognised as being affected in several neurodegenerative diseases, including Alzheimer's disease. Using over 120,000 individual cells from macaques (whose cortical organisation is among the closest to humans), the researchers identified 78 molecularly defined cell types, including 20 distinct excitatory neuron types. They then combined this with Patch-seq, microscopy and electrophysiology to link gene-expression profiles with the actual shape and electrical behaviour of neurons.

One of the 20 excitatory neuron types was labelled Exc FEZF2 COL24A1. FEZF2 identified the broader family of deep-layer projection neurons, while COL24A1 was one of the genes most specifically enriched in that particular neuronal population. This is notable because modern neuroscience increasingly recognises that many neurological diseases, including Alzheimer's, affect specific excitatory neuronal populations rather than all neurons equally.

The authors then looked more closely at this COL24A1-containing population because it included von Economo neurons (VENs)—a rare class of specialised projection neurons found mainly in humans, great apes and a few other highly social mammals. Within this population they identified five further molecular subtypes, one of which was labelled COL24A1 POC5 and corresponded to the VEN-S subtype. They also experimentally confirmed COL24A1 expression in these neurons using molecular staining.

The paper does not suggest COL24A1 causes disease or that it has a particular function in these neurons. Rather, its significance is that COL24A1 repeatedly emerged as a statistically enriched marker during progressively finer levels of analysis—from helping define one of the 20 excitatory neuron types, to helping define a more specialised VEN-related subtype. In other words, COL24A1 was not simply present in the brain; it consistently helped distinguish increasingly specific neuronal identities.

Interestingly, this finding adds to a broader pattern emerging across independent single-cell studies. COL24A1 has now also been identified as a marker of specialised neuronal populations in the human entorhinal cortex and subiculum/hippocampus. Across these studies, COL24A1 repeatedly appears in specialised excitatory neuronal populations, with the present study further identifying it within a deep-layer projection-neuron population. While each study addressed a different biological question, together they suggest COL24A1 repeatedly marks biologically distinct neuronal identities across multiple brain regions, supporting the idea that its neuronal expression is structured rather than incidental."

https://www.nature.com/articles/s41556-026-02009-4

Expect that well over 1 million shares of AVXL stock will be bought today!!!

Good luck and GOD bless,

The "murine(mouse)" models that were gonna win Missling the Nobel? 

Wow, absolutely great for the rats. I bet the FDA will be absolutely impressed.

The 30 day RSI remains below 50 so lots of potential upside remains.

Like you I await news on any developments, new or old, since Terrie has taken the reins. Perhaps today's action suggests new information is on the horizon?

Does the RSI suggest we are about to move higher?

Notice that the RSI is above "50" now at 52.+ and just as high as when the stock traded at $3 about 16 days ago...it's good signal with 50 being the favored index level for watchers....also, the 50 sma is around $2.88, so that would be nice to see!

Volume would need to go much higher for a penetration!

Still very disappointed that not a whisper from Terrie Kellmeyer....

Interesting that the crude prices have dropped so much....good back drop.

https://finviz.com/futures_charts?p=d&t=CL

Nice to see the AM action today.

Need to break through $2.80 and stay there to support the notion of a new uptrend!

Still nothing from these scammers? Pathetic

It may be the murines are really happy,,,

So what? Meaningless for Anavex.

Sigma-1 receptor agonist SA4503 improves cerebral protective effects in an extracorporeal cardiopulmonary resuscitation rat model

https://pmc.ncbi.nlm.nih.gov/articles/PMC13316324/

Good luck and GOD bless,

Yes

You’re welcome. And again, thank you for your patience.

That letter looks more professional than this for the past 8 weeks:

Thank you for the update Terrie.

I guess Miss Communication was brought in to run the stock into the dirt and then sell the company for peanuts.

The only thing that’s silly is all the nonsense (and worse) that has been spewed on this board for years. As for Anavex, I have been consistently right. I know how much that hurts.

The lack of communication from Anavex is a tell. Wouldn’t it be nice if they said something like this:

Dear stockholders,

Thank you for your patience during this period since I became interim CEO. For the past two months we and our consultants have undertaken a thorough review of all the data from every trial the company has done. At this time we are satisfied as to the integrity of our data. We believe Blarcamesine has shown itself to be both safe and efficacious and we are determined to move ahead with additional trials in Alzheimer’s disease as well as other indications.

Over the next several months we will be building a new team to ensure the integrity of our research and drive positive outcomes. Fortunately, our financial position is strong. We have the resources we need to conduct our research and clinical trials over the next several years. However, should we need additional capital, we are confident we can raise the funds we need through partnerships and/or from institutional biotech investors.

We believe the future of Anavex is bright. We are excited to start anew and build a world-class biotech company and rebuild credibility with our valued shareholders and partners.

Again, we thank you for your patience. We will do everything possible to enhance shareholder value, which is our primary responsibility.

Should you have any questions, please feel free to contact us through our investor relations firm. We will endeavor to respond to you as quickly and a fully as possible.

I look forward to speaking with you on a conference call in the not too distant future.

Best,

Silly response with all the time you spend here. As if you don’t have an agenda beyond saving shareholders. You’re fooling no one with any common sense.

It’s true. I do find this board entertaining. As for Anavex, I continue to believe nothing matters except a large, well designed and executed phase 3 trial in AD. Assuming Anavex is still around, which seems unlikely, and does the trial, which also seems unlikely, we may have an answer in the early 2030s. That gives me many years to continue to enjoy the entertainment.

Take care not to allow your hopes, fears, and greed to drive your investment decisions.

So what?

Sigma 1 Receptor Activation Coordinates Metabolic Stress Responses to Protect Retinal Vasculature in Ischemic Retinopathy

https://iovs.arvojournals.org/article.aspx?articleid=2817981

Good luck and GOD bless,

“ Anyway, none of it matters.”

Sure it matters. That’s why you are here “entertaining” yourself.

The Anavex fiasco is there for all to see. Distractions like how many shares are bought or posting the video of Ern for the millionth time no longer hold water. The pumping continues but his well has run dry.

Everybody (well almost everybody) finally realizes that Missling was a disaster waiting to happen and the stock price collapse was inevitable. It was just a matter of time. The only cabal at work was Missling and the board members.

In the unlikely event Anavex survives, it’ll take a well designed and executed Phase 3 trial to determine once and for all whether Blarcamesine is safe and effective. It’ll be 2030 or 2031 before we know. How many shares bought or sold every day is immaterial and a distraction. Posting the Ern video again and again smacks of delusion or desperation. Anyway, none of it matters.

Well you never know how many shares are purchased you only know how many are shared but you like to say bought, nobody really cares we're much more interested and not losing a penny today when the stock market is way up... as far as your prediction of 5 million shares bought today you only missed by 4.5 million but good try

What is the true value of Anavex? The market cap around 250 million, with perhaps 110 million or so in cash. But it has no products, and it has a burn rate for the expenses and the employees. Where are the massive layoffs? (everybody should be layed off immediately). So it should not even sell for 110 million market cap, not with no conceivable drug candidates and a burn rate of what, 10 million annually? Presuming it will take 3 years for the sole employee (hopefully) to go out and get an actual drug candidate for phase one clinical testing.........and all the expense and risks of clinical trials, it should sell for perhaps a 30 - million dollar market cap....Perhaps 30 or 40 cents, absolute max, The so called company, it is not actually a company should come out and tell the public that it is deep sixing this so called BlahBlah-casimine liquid, but the stock would go to its true value almost over night. And so you see, this is the Dream scenario of retail investors and the anon funds who just buy an index where AVXL might make up .05% of the composition. It is not even junk. At least Fred Sanford and his son "the dummie" made money as junk collectors. It is garbage, and only Tony soprano made money from garbage. insert-text-here